Aquinox Pharmaceuticals Inc (AQXP.OQ)
20 Sep 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2014||Co-Founder, President and Chief Executive Officer and Chairman of the Board|
|40||2011||Chief Financial Officer, Vice President - Finance|
|48||2017||Chief Operating Officer, Vice President - R&D Operations|
|59||2014||Vice President - Global Regulatory Affairs & Quality Assurance|
|48||2016||Chief Medical Officer, Vice President - Clinical Development|
- UPDATE 2-Aquinox to stop development of lead drug; shares plunge
- Aquinox Pharma's bladder pain drug fails to meet study goal
- BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals
- BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan